相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multi-targeted approach in the treatment of thyroid cancer
Herbert Chen
Therapeutics and Clinical Risk Management (2016)
Anaplastic thyroid cancer, tumorigenesis and therapy
J. P. O'Neill et al.
IRISH JOURNAL OF MEDICAL SCIENCE (2010)
Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Andrew M. Wardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Elaine T. Lam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Emerging molecular therapies of advanced thyroid cancer
Maria Graziella Catalano et al.
MOLECULAR ASPECTS OF MEDICINE (2010)
Advances in Cellular Therapy for the Treatment of Thyroid Cancer
Claudia Papewalis et al.
JOURNAL OF ONCOLOGY (2010)
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
V. Gregorc et al.
BRITISH JOURNAL OF CANCER (2009)
Identification of Polo-like Kinase 1 as a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma
Tito Claudio Nappi et al.
CANCER RESEARCH (2009)
Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Laura A. Marlow et al.
CANCER RESEARCH (2009)
Targeting the ubiquitin-proteasome system for cancer therapy
Yili Yang et al.
CANCER SCIENCE (2009)
Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells
Alessandro Antonelli et al.
CLINICAL ENDOCRINOLOGY (2009)
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
Jeffrey A. Knauf et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Successful Treatment of Anaplastic Thyroid Carcinoma with a Combination of Oral Valproic Acid, Chemotherapy, Radiation and Surgery
Hitoshi Noguchi et al.
ENDOCRINE JOURNAL (2009)
MOLECULARLY TARGETED THERAPIES FOR THYROID CANCERS
Steven I. Sherman
ENDOCRINE PRACTICE (2009)
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Robert C. Smallridge et al.
ENDOCRINE-RELATED CANCER (2009)
New therapeutic advances in the management of progressive thyroid cancer
Jennifer A. Woyach et al.
ENDOCRINE-RELATED CANCER (2009)
Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
Stephane Oudard et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer
C. Papewalis et al.
HORMONE AND METABOLIC RESEARCH (2009)
R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-κB pathway
Michela Festa et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer
Rebecca E. Schweppe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
A Small-Molecule Triptolide Suppresses Angiogenesis and Invasion of Human Anaplastic Thyroid Carcinoma Cells via Down-Regulation of the Nuclear Factor-kappa B Pathway
Wenbo Zhu et al.
MOLECULAR PHARMACOLOGY (2009)
Cancer Genomes on a Shoestring Budget
Jay Shendure et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome
Colin J. Mooney et al.
THYROID (2009)
Targeting Epidermal Growth Factor Receptor 1 Signaling in Human Thyroid-Stimulating Hormone-Independent Thyroid Carcinoma FRO Cells Results in a More Chemosensitive and Less Angiogenic Phenotype
Matteo Landriscina et al.
THYROID (2009)
Distinct Genetic Alterations in the Mitogen-Activated Protein Kinase Pathway Dictate Sensitivity of Thyroid Cancer Cells to Mitogen-Activated Protein Kinase Kinase 1/2 Inhibition
Rebecca E. Schweppe et al.
THYROID (2009)
Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib
Thomas Hogan et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2009)
Molecular pathology of thyroid cancer: diagnostic and clinical implications
James A. Fagin et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Dedifferentiated thyroid cancer: A therapeutic challenge
Alessandro Antonelli et al.
BIOMEDICINE & PHARMACOTHERAPY (2008)
ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice
H. V. Reddi et al.
CANCER GENE THERAPY (2008)
Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells
Shu Takakura et al.
CANCER SCIENCE (2008)
Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus d/922-947
Silvana Libertini et al.
CLINICAL CANCER RESEARCH (2008)
Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer
Shu-Fu Lin et al.
CLINICAL CANCER RESEARCH (2008)
In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma
Joshua P. Klopper et al.
CLINICAL CANCER RESEARCH (2008)
Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests
Alessandro Antonelli et al.
CLINICAL ENDOCRINOLOGY (2008)
Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope
Hari A. Deshpande et al.
CURRENT OPINION IN ONCOLOGY (2008)
Treatment of recurrent thyroid cancers - is there a light in the horizon?
Rodrigo Kraft Rovere et al.
CURRENT OPINION IN ONCOLOGY (2008)
Poorly differentiated thyroid carcinoma: Diagnostic features and controversial issues
Marco Volante et al.
ENDOCRINE PATHOLOGY (2008)
Peroxisome proliferator-activated receptor γ inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent
D. Bonofiglio et al.
ENDOCRINE-RELATED CANCER (2008)
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
Yannick Arlot-Bonnemains et al.
ENDOCRINE-RELATED CANCER (2008)
Dehydroxymethylepoxyquinomicin, a Novel Nuclear Factor-κB Inhibitor, Enhances Antitumor Activity of Taxanes in Anaplastic Thyroid Cancer Cells
Zhaowei Meng et al.
ENDOCRINOLOGY (2008)
Early clinical studies of novel therapies for thyroid cancers
Steven I. Sherman
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2008)
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia
John E. Paes et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2008)
Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model
Naomi Shimazaki et al.
EUROPEAN JOURNAL OF CANCER (2008)
Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration
Alessandro Antonelli et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
The new paradigm of flow cell sequencing
Robert A. Holt et al.
GENOME RESEARCH (2008)
The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice
Weidong Su et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Oncolytic Vaccinia Virotherapy of Anaplastic Thyroid Cancer in Vivo
Shu-Fu Lin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification
Rebecca E. Schweppe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of sorafenib in advanced thyroid cancer
Vandana Gupta-Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
Elisa Sala et al.
MOLECULAR CANCER RESEARCH (2008)
Gefitinib (Iressa) Potentiates the Effect of Ionizing Radiation in Thyroid Cancer Cell Lines
Jay Patrick Lopez et al.
LARYNGOSCOPE (2008)
Next-generation DNA sequencing
Jay Shendure et al.
NATURE BIOTECHNOLOGY (2008)
The neutrophil gelatinase-associated lipocalin (NGAL), a NF-κB-regulated gene, is a survival factor for thyroid neoplastic cells
Alessio Lannetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A phase II study of gefitinib in patients with advanced thyroid cancer
Nathan A. Pennell et al.
THYROID (2008)
BRAF mutation in papillary thyroid cancer:: Pathogenic role, molecular bases, and clinical implications
Mingzhao Xing
ENDOCRINE REVIEWS (2007)
New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy
Garcilaso Riesco-Eizaguirre et al.
ENDOCRINE-RELATED CANCER (2007)
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244
Douglas W. Ball et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus
Shu-Fu Lin et al.
SURGERY (2007)
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines
Jay Patrick Lopez et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2007)
RAR and RXR modulation in cancer and metabolic disease
Lucia Altucci et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Involvement of glyceraldehyde-3-phosphate dehydrogenase in tumor necrosis factor-related apoptosis-inducing ligand-mediated death of thyroid cancer cells
Zhen-Xian Du et al.
ENDOCRINOLOGY (2007)
Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model
Sai-Ching J. Yeung et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma
Sam M. Wiseman et al.
ARCHIVES OF SURGERY (2007)
The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model
Fernando Gomez-Rivera et al.
CLINICAL CANCER RESEARCH (2007)
Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas
Kenneth B. Ain et al.
THYROID (2007)
New trends in the treatment of undifferentiated carcinomas of the thyroid
Paolo Miccoli et al.
LANGENBECKS ARCHIVES OF SURGERY (2007)
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice
Seungwon Kim et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Targeting the ubiquitin-proteasome pathway in cancer therapy
Yuki Ishii et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death
Concetta Conticello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years
Enrico Brignardello et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines
S. Hoffmann et al.
ENDOCRINE (2007)
A conditionally replicative, Wnt/β-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer
P. H. Abbosh et al.
CANCER GENE THERAPY (2007)
Targeting BRAFV600E in thyroid carcinoma:: therapeutic implications
Constantine S. Mitsiades et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Anaplastic thyroid carcinoma: Expression profile of targets for therapy offers new insights for disease treatment
Sam M. Wiseman et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma
Christopher N. Prichard et al.
LARYNGOSCOPE (2007)
The optimal use of bexarotene in cutaneous T-cell lymphoma
R. Gniadecki et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines
Maria G. Catalano et al.
ENDOCRINE-RELATED CANCER (2007)
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
Matthew G. Fury et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells
Maria G. Catalano et al.
JOURNAL OF ENDOCRINOLOGY (2006)
Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells
Junichi Kurebayashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line
Hwanjeong Jeong et al.
NUCLEAR MEDICINE AND BIOLOGY (2006)
Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: Mutational and functional analysis
Constantine S. Mitsiades et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues
Salvatore Ulisse et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma
Sam M. Wiseman et al.
AMERICAN JOURNAL OF SURGERY (2006)
Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy:: Modulation by peroxisome proliferator-activated receptor-γ agonists
A Antonelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice
S Kim et al.
CLINICAL CANCER RESEARCH (2006)
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788
S Kim et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines
JW Park et al.
THYROID (2005)
Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells
MG Catalano et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Emerging role of rexinoids in non-small cell lung cancer: Focus on bexarotene
JR Rigas et al.
ONCOLOGIST (2005)
Tumor lysis syndrome in a multiple myeloma treated with thalidomide
N Fuente et al.
ANNALS OF ONCOLOGY (2004)
A phase II study using retinoids as re differentiation agents to increase iodine uptake in metastatic thyroid cancer
SC Short et al.
CLINICAL ONCOLOGY (2004)
Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers
JC Philips et al.
NUCLEAR MEDICINE COMMUNICATIONS (2004)
Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
C Grommes et al.
LANCET ONCOLOGY (2004)
Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury
J Mishra et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Anaplastic transformation of thyroid cancer: Review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy
SM Wiseman et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2003)
Molecular pathogenesis of thyroid cancer
DL Segev et al.
SURGICAL ONCOLOGY-OXFORD (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Retinoic acid for redifferentiation of thyroid cancer -: does it hold its promise?
T Grüning et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
L Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Anaplastic thyroid cancer evolved from papillary carcinoma - Demonstration of anaplastic transformation by means of the inter-simple sequence repeat polymerase chain reaction
SM Wiseman et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2003)
Insular and anaplastic carcinoma of the thyroid - A 45-year comparative study at a single institution and a review of the significance of p53 and p21
KY Lam et al.
ANNALS OF SURGERY (2000)
分享论文
